Akorn Inc (AKRX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Akorn Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012270
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:76
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akorn Inc (Akorn) is a pharmaceutical company which carries out the development, manufacturing and commercialization of generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its products in various sterile and non-sterile dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn offers its products and services to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. It operates manufacturing facilities in India and the US. The company has presence in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.

Akorn Inc (AKRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Akorn Inc, Medical Devices Deals, 2011 to YTD 2017 12
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Akorn Inc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 16
Oak Pharma Acquires Tafluprost Business from Merck 17
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 18
Akorn Acquires Betimol, Opthalmic Drug, From Santen 19
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 20
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 21
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 22
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 24
Hi-Tech Pharmacal Acquires Rights To Branded Products From Atley Pharma 25
Hi-Tech Pharmacal Acquires Nystatin Oral Suspension ANDA From Bausch & Lomb 26
Partnerships 27
Knight Therapeutics Enters into Distribution Agreement with Akorn 27
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 28
Elite Pharma Enters Into Co-Development Agreement With Hi-Tech Pharmacal 29
Licensing Agreements 30
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 30
Akorn Enters Into Licensing Agreement With Aciex Therapeutics 31
Santen Pharma Enters into Licensing Agreement with Oak Pharma 32
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 33
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 34
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 35
Hi-Tech Pharmacal Enters Into Licensing Agreement With KVK-Tech For Lodrane 36
Inspire Pharma Amends Licensing Agreement With Yamasa 37
Debt Offering 38
Akorn Completes Private Placement Of Convertible Senior Notes Due 2016 For US$120 Million 38
Asset Transactions 39
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 39
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 41
Acquisition 42
Fresenius to Acquire Akorn 42
Akorn Acquires VersaPharm from Tailwind Capital Partners 44
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 46
Akorn Completes Acquisition Of Hi-Tech Pharmacal For US$640 Million 47
Akorn Acquires Inspire Pharma From Merck For US$53 Million 49
Serum Institute Plans To Sell Its Stake In Akorn 51
Akorn To Acquire Minority Stake In Aciex Therapeutics 53
Merck Completes Acquisition Of Inspire Pharma 54
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 56
Akorn Acquires Advanced Vision Research For US$26 Million 57
Akorn Inc – Key Competitors 58
Akorn Inc – Key Employees 59
Akorn Inc – Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Joint Venture 61
Recent Developments 62
Financial Announcements 62
Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance 62
Nov 03, 2016: Akorn Provides Third Quarter 2016 Results 64
Aug 04, 2016: Akorn Provides Second Quarter 2016 Results 65
May 16, 2016: Akorn Provides First Quarter 2016 Results 66
May 10, 2016: Akorn Completes 2014 Financial Statement Restatement and Reports Audited 2015 and Restated 2014 Results 68
Mar 22, 2016: Akorn Provides Preliminary Unaudited Full Year 2015 Financial Results and Issues 2016 Financial Guidance 70
Jan 14, 2016: Akorn Provides Material Updates 72
Corporate Communications 73
Mar 07, 2016: Akorn Receives Expected Additional Delinquency Notice From Nasdaq 73
Jan 21, 2016: Akorn Appoints Greg Lawless as Chief Human Resources Officer 74
Legal and Regulatory 75
Dec 12, 2016: Akorn Announces Completion of FDA Re-inspection of Decatur Facility 75
Appendix 76
Methodology 76
About GlobalData 76
Contact Us 76
Disclaimer 76

List of Tables
Akorn Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Akorn Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Akorn Inc, Medical Devices Deals, 2011 to YTD 2017 12
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 16
Oak Pharma Acquires Tafluprost Business from Merck 17
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 18
Akorn Acquires Betimol, Opthalmic Drug, From Santen 19
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 20
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 21
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 22
Oak Pharma Acquires Three Hospital-Based Injectables From H. Lundbeck 24
Hi-Tech Pharmacal Acquires Rights To Branded Products From Atley Pharma 25
Hi-Tech Pharmacal Acquires Nystatin Oral Suspension ANDA From Bausch & Lomb 26
Knight Therapeutics Enters into Distribution Agreement with Akorn 27
Hi-Tech Pharmacal Enters Into Co-Marketing Agreement With Mallinckrodt For TussiCaps 28
Elite Pharma Enters Into Co-Development Agreement With Hi-Tech Pharmacal 29
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 30
Akorn Enters Into Licensing Agreement With Aciex Therapeutics 31
Santen Pharma Enters into Licensing Agreement with Oak Pharma 32
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 33
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 34
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 35
Hi-Tech Pharmacal Enters Into Licensing Agreement With KVK-Tech For Lodrane 36
Inspire Pharma Amends Licensing Agreement With Yamasa 37
Akorn Completes Private Placement Of Convertible Senior Notes Due 2016 For US$120 Million 38
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 39
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 41
Fresenius to Acquire Akorn 42
Akorn Acquires VersaPharm from Tailwind Capital Partners 44
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 46
Akorn Completes Acquisition Of Hi-Tech Pharmacal For US$640 Million 47
Akorn Acquires Inspire Pharma From Merck For US$53 Million 49
Serum Institute Plans To Sell Its Stake In Akorn 51
Akorn To Acquire Minority Stake In Aciex Therapeutics 53
Merck Completes Acquisition Of Inspire Pharma 54
Metrics Acquires Midlothian Labs From Hi-Tech Pharmacal 56
Akorn Acquires Advanced Vision Research For US$26 Million 57
Akorn Inc, Key Competitors 58
Akorn Inc, Key Employees 59
Akorn Inc, Subsidiaries 60
Akorn Inc, Joint Venture 61

★海外企業調査レポート[Akorn Inc (AKRX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsubishi Logistics Corporation
    Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Logistics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • DexCom Inc (DXCM):企業の製品パイプライン分析
    Summary Dexcom Inc (Dexcom) is a medical device company that designs, develops and commercializes continuous glucose monitoring (CGM) systems. The company’s major products include integrated CGM systems for adults and pediatric use, Dexcom G5 mobile CGM system, Dexcom G4 PLATINUM CGM system, associa …
  • Sinofert Holdings Ltd (297):企業の財務・戦略的SWOT分析
    Sinofert Holdings Ltd (297) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Apricus Biosciences Inc (APRI):製薬・医療:M&Aディール及び事業提携情報
    Summary Apricus Biosciences Inc (Apricus) develops and commercializes pharmaceutical products indicated for the treatment of various therapeutic classes including urology and rheumatology. Its product pipeline includes, Vitaros (alprostadil), a topical vasodilator cream in-licensed from Warner Chilc …
  • Heartland Financial USA, Inc.:企業のM&A・事業提携・投資動向
    Heartland Financial USA, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Heartland Financial USA, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Selex Gruppo Commerciale S.p.A.:戦略・SWOT・企業財務分析
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Fraport Slovenija, d.o.o.:企業の戦略・SWOT・財務情報
    Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Fraport Slovenija, d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Turkiye Halk Bankasi AS:企業の戦略・SWOT・財務分析
    Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report Summary Turkiye Halk Bankasi AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務情報
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • MicuRx Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary MicuRx Pharmaceuticals Inc (MicuRx) is a developer of antibiotics for drug-resistant bacterial infections. The company develops a pipeline of antimicrobial agents using its proprietary drug discovery platform to treat both gram-positive and gram-negative bacterial infections. Its lead produc …
  • China Overseas Land & Investment Limited:企業の戦略・SWOT・財務情報
    China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report Summary China Overseas Land & Investment Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Yoshinoya Holdings Co Ltd:企業の戦略・SWOT・財務分析
    Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yoshinoya Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Cumberland Pharmaceuticals Inc (CPIX)-製薬・医療分野:企業M&A・提携分析
    Summary Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a pharmaceutical company which develops and commercializes branded prescription products. The company’s product portfolio includes acetylcysteine, ibuprofen, lactulose, conivaptan, amifostine and ifetroban. It provides prescription produc …
  • Strabag SE:企業のM&A・事業提携・投資動向
    Strabag SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Strabag SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Acciona Energia SA:電力:M&Aディール及び事業提携情報
    Summary Acciona Energy, S.A. (Acciona Energy) formerly Corporacion Energia Hidroelectrica de Navarra, S.A., is a renewable energy company. It owns and operates renewable-based and cogeneration electricity generation assets. The company generates and distributes electricity in Spain. It generates ele …
  • Heathrow Airport Holdings Limited:企業の戦略・SWOT・財務分析
    Heathrow Airport Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Heathrow Airport Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Batory Foods, Inc.:企業の戦略・SWOT・財務情報
    Batory Foods, Inc. - Strategy, SWOT and Corporate Finance Report Summary Batory Foods, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Bioaster:製薬・医療:M&Aディール及び事業提携情報
    Summary Bioaster is a technology research institute that develops technologies and conducts research on infectious diseases and microbiology. The institute offers services in the therapeutic areas of respiratory diseases, diarrhea, AIDS and tuberculosis. It carries out technological research program …
  • Bank of Communications Ltd (601328):企業の財務・戦略的SWOT分析
    Bank of Communications Ltd (601328) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Medikit Co Ltd (7749):企業の財務・戦略的SWOT分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆